tbuckley/cabot-search huggingface dataset:
Air Quality and Brain Health
Authors: Anita Slomski
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OUTCOMES IN PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION AND ACUTE NONISCHEMIC MYOCARDIAL INJURY ADMITTED FOR NON-CARDIAC CAUSE
Authors: Roman Zeltser, Lawrence M. Zeltser, Kayla D. Finuf, Myia S. Williams, Renee Pekmezaris, Amgad N. Makaryus
Journal: Journal of the American College of Cardiology (2022)
A SYSTEMATIC REVIEW ON ECHOCARDIOGRAPHIC FINDINGS OF MYOCARDITIS AFTER THE SECOND COVID-19 MRNA VACCINATION DOSE
Authors: Sarah Elsayed, Malaz Joda, Wiam Awad Saeed Sadoon, Mohammed B. Ibrahim, Ali Elkhedr, Lina Alatta, Nadir G. Abdelrahman, Senthil Thambidorai
Journal: Journal of the American College of Cardiology (2022)
PREVALENCE AND CHARACTERISTICS OF HEART FAILURE WITH PRESERVED, MILDLY REDUCED, AND REDUCED EJECTION FRACTION IN SPAIN: A RETROSPECTIVE COHORT STUDY USING BIGPAC DATABASE
Authors: Mai Duong, Hungta Chen, Nahila Justo, Javier Cid-Ruzafa, Ignacio Hernandez, Luis Varela, Beatriz Palacios, Phillip Hunt, Juan F. Delgado
Journal: Journal of the American College of Cardiology (2022)
Extraskeletal Ewing sarcoma of the duodenum presenting as duodenojejunal intussusception
Authors: Razeen Hassan, Leow Voon Meng, Kee Thian Ngee, Lim I-Vern, Padmaan Sankaran, Lim Choon Hean, Lee Euxian, Haidi Mohamad, Noraini Mohd Dusa, Manisekar Subramaniam
Journal: The Lancet (2022)
Decade-Long CLL Remission After CAR T-Cell Therapy Reported
Authors: Jennifer Abbasi
Journal: JAMA (2022)

More than 10 years after 2 patients with end-stage chronic lymphocytic leukemia (CLL) received tisagenlecleucel, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, a group of highly activated CAR T cells were still proliferating in their blood, keeping the cancer at bay.
Abstract P3-10-02: Enhanced miR-579-3p by anti-estrogen treatment may affect capecitabine response in hormone receptor positive metastatic breast cancer
Authors: Jieun Lee, Seung Yeon Joe, Ji-Sun Lee, Dong-Min Kim, Ahwon Lee
Journal: Cancer Research (2022)

Abstract Purpose Capecitabine is one of a treatment option in anthracycline and taxane pre-treated metastatic breast cancer (MBC) patients. We have performed miRNA microarray of durable and poor responders to capcitabine, and compared with cell line miRNA expression profile (MCF-7, tamoxifen-resistant MCF-7 [MCF-TAM] cell line treated with 5-FU. Methods Between Jan 2006 to Jan 2021, 66 patients treated with capecitabine after anthracycline and taxane failure were enrolled. Twenty-three archival tumor tissues (11 durables and 12 poor responders, each) were collected and went through nCounter miRNA expression assay. MCF-7, tamoxifen resistant MCF-7 (MCF-TAM) cell line was treated with tamoxifen or 5-FU for proliferation assay and also went through nCounter miRNA expression assay. Results HR positive patients who received anti-estrogen treatment before capecitabine showed longer PFS (median 7.7 vs. 4.03 months, P=0.006). MCF-7 treated with tamoxifen and 5-FU showed decreased proliferation compared to 5-FU treated MCF-7. There was significant difference of miR-579-3p expression between durable and poor responders (log2FC -3.02, P=0.004). Tamoxifen-treated MCF-7 cell line showed upregulation of miR-579-3p compared to MCF-7. Tamoxifen + 5-FU treated MCF-7 cell line showed decreased expression of miR-579-3p compared to 5-FU treated MCF-7 cell line. MCF-7 cell line was treated with 5-FU and miR-579-3p. Compared to 5-FU only treated cell line, 5-FU + miR-579-3p treated cell line showed trends for decreased cell proliferation, suggesting that miR-579-3p may have chemo-sensitizing role during systemic chemotherapy. Based on miRNA database, authors hypothesized that MDM2 may be target protein of miR-579-3p and planning to perform further analysis. Conclusions Anti-estrogen treatment before capecitabine administration was associated to better survival in HR positive MBC. Anti-estrogen potentiated the effect of 5-FU in MCF-7. MiR-579-3p was upregulated in durable responders and tamoxifen treated MCF-7 cell line. Further study is planned to analyze the role of miR-579-3p and its potential target, MDM2 in breast cancer. Citation Format: Jieun Lee, Seung Yeon Joe, Ji-Sun Lee, Dong-Min Kim, Ahwon Lee. Enhanced miR-579-3p by anti-estrogen treatment may affect capecitabine response in hormone receptor positive metastatic breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-10-02.
Eosinophils are an essential element of a type 2 immune axis that controls thymus regeneration
Authors: Emilie J. Cosway, Andrea J. White, Sonia M. Parnell, Edina Schweighoffer, Helen E. Jolin, Andrea Bacon, Hans-Reimer Rodewald, Victor Tybulewicz, Andrew N. J. McKenzie, William E. Jenkinson, Graham Anderson
Journal: Science Immunology (2022)

Therapeutic interventions used for cancer treatment provoke thymus damage and limit the recovery of protective immunity. Here, we show that eosinophils are an essential part of an intrathymic type 2 immune network that enables thymus recovery after ablative therapy. Within hours of damage, the thymus undergoes CCR3-dependent colonization by peripheral eosinophils, which reestablishes the epithelial microenvironments that control thymopoiesis. Eosinophil regulation of thymus regeneration occurs via the concerted action of NKT cells that trigger CCL11 production via IL4 receptor signaling in thymic stroma, and ILC2 that represent an intrathymic source of IL5, a cytokine that therapeutically boosts thymus regeneration after damage. Collectively, our findings identify an intrathymic network composed of multiple innate immune cells that restores thymus function during reestablishment of the adaptive immune system.
CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype
Authors: Han Li, Fan Luo, Xingyu Jiang, Weijing Zhang, Tong Xiang, Qiuzhong Pan, Liming Cai, Jingjing Zhao, Desheng Weng, Yue Li, Yuhu Dai, Fengze Sun, Chaopin Yang, Yue Huang, Jieying Yang, Yan Tang, Yulong Han, Mian He, Yanna Zhang, Libing Song, Jian-Chuan Xia
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Platinum resistance is a major challenge in the clinical treatment of advanced ovarian cancer (OC). Accumulating evidence shows that the tumor-promotive M2 macrophage is linked to the limiting chemotherapy efficacy of multiple malignancies including OC. Circular RNAs (circRNAs) are a novel class of non-coding RNAs which function as the critical regulator in biological process of cancer. However, their impact on macrophage polarization and chemoresistance of OC remain unclear. Methods Platinum-resistant circRNAs were screened using circRNA deep sequencing and validated using in situ hybridization in OC tissues with or without platinum resistance. The role of circITGB6 in inducing cisplatin (CDDP) resistance was evaluated by clone formation, immunofluorescence and annexin V assays in vitro, and by intraperitoneal tumor model in vivo. The mechanism underlying circITGB6-mediated tumor-associated macrophage (TAM) polarization into M2 phenotype was investigated using RNA pull-down, luciferase reporter, electrophoretic mobility shift, RNA binding protein immunoprecipitation (RIP), ELISA and immunofluorescence assays. Results We identified that a novel circRNA, circITGB6, robustly elevated in tumor tissues and serums from patients with OC with platinum resistance, was correlated with poor prognosis. circITGB6 overexpression promoted an M2 macrophage-dependent CDDP resistance in both vivo and vitro. Mechanistic research determined that circITGB6 directly interacted with IGF2BP2 and FGF9 mRNA to form a circITGB6/IGF2BP2/FGF9 RNA–protein ternary complex in the cytoplasm, thereby stabilizing FGF9 mRNA and inducing polarization of TAMs toward M2 phenotype. Importantly, blocking M2 macrophage polarization with an antisense oligonucleotide targeting circITGB6 markedly reversed the circITGB6-induced CDDP resistance of OC in vivo. Conclusions This study reveals a novel mechanism for platinum resistance in OC and demonstrates that circITGB6 may serve as a potential prognostic marker and a therapeutic target for patients with OC.
RATES OF GUIDELINE DIRECTED MEDICAL THERAPY IN PATIENTS WITH CRITICAL LIMB ISCHEMIA UNDERGOING MAJOR AMPUTATION: INSIGHTS FROM THE NATIONAL CERNER HEALTH FACTS ELECTRONIC HEALTH RECORD DATABASE
Authors: Jeremy Provance, John A. Spertus, Mark Hoffman, Philip Jones, Matthew C. Bunte, Todd Vogel, Carlos Mena-Hurtado, Kim G.E. Smolderen
Journal: Journal of the American College of Cardiology (2022)
Complement <i>C4</i>, the Major Histocompatibility Complex, and Autoimmunity
Authors: Timothy J. Vyse, Betty P. Tsao
Journal: Arthritis & Rheumatology (2022)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)
Authors: Juxian Sun, Rongping Guo, Xinyu Bi, Mengchao Wu, Zhaoyou Tang, Wan Yee Lau, Shusen Zheng, Xuehao Wang, Jinming Yu, Xiaoping Chen, Jia Fan, Jiahong Dong, Yongjun Chen, Yunfu Cui, Chaoliu Dai, Chihua Fang, Shuang Feng, Zhili Ji, Weidong Jia, Ningyang Jia, Gong Li, Jing Li, Qiu Li, Jiangtao Li, Tingbo Liang, Lianxin Liu, Shichun Lu, Yi Lv, Yilei Mao, Yan Meng, Zhiqiang Meng, Feng Shen, Jie Shi, Huichuan Sun, Kaishan Tao, Gaojun Teng, Xuying Wan, Tianfu Wen, Liqun Wu, Jinglin Xia, Mingang Ying, Jian Zhai, Leida Zhang, Xuewen Zhang, Zhiwei Zhang, Haiping Zhao, Donghai Zheng, Xuting Zhi, Jie Zhou, Cuncai Zhou, Jian Zhou, Zhaochong Zeng, Kangshun Zhu, Minshan Chen, Jianqiang Cai, Shuqun Cheng
Journal: Liver Cancer (2022)

Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials.
Statistical and machine learning methods for spatially resolved transcriptomics data analysis
Authors: Zexian Zeng, Yawei Li, Yiming Li, Yuan Luo
Journal: Genome biology (2022)

Abstract The recent advancement in spatial transcriptomics technology has enabled multiplexed profiling of cellular transcriptomes and spatial locations. As the capacity and efficiency of the experimental technologies continue to improve, there is an emerging need for the development of analytical approaches. Furthermore, with the continuous evolution of sequencing protocols, the underlying assumptions of current analytical methods need to be re-evaluated and adjusted to harness the increasing data complexity. To motivate and aid future model development, we herein review the recent development of statistical and machine learning methods in spatial transcriptomics, summarize useful resources, and highlight the challenges and opportunities ahead.
RENIN-ANGIOTENSIN SYSTEM (RAS) INHIBITION IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AND ADVANCED KIDNEY DISEASE
Authors: Evangelos Kanonidis, Amiya Ahmed, Samir Patel, Charles Faselis, Prakash C. Deedwania, Ioannis Kanonidis, Phillip Hong Lam, Venkatesh K. Raman, Richard M. Allman, Gregg C. Fonarow, Ali Ahmed
Journal: Journal of the American College of Cardiology (2022)
Serology Test Results and Other Important Characteristics of Patients With Persistent COVID-19 Symptoms
Authors: Yochai Re’em, Menelaos Symeonides, Lisa McCorkell
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Exposure to World Health Organization's AWaRe antibiotics and isolation of multidrug resistant bacteria: a systematic review and meta-analysis
Authors: Giorgia Sulis, Sena Sayood, Shashi Katukoori, Neha Bollam, Ige George, Lauren H. Yaeger, Miguel A. Chavez, Emmanuel Tetteh, Sindhu Yarrabelli, Celine Pulcini, Stephan Harbarth, Dominik Mertz, Mike Sharland, Lorenzo Moja, Benedikt Huttner, Sumanth Gandra
Journal: Clinical Microbiology and Infection (2022)
ASSESSMENT OF HEART SOUNDS AS PREDICTORS OF REHOSPITALIZATIONS USING A NONINVASIVE MULTIPLE SENSOR MONITORING DEVICE
Authors: Mohammad Ahmed, Prashanth Shyam Kumar, Carly Maucione, Katherine Julian, Frank Weigel, Patrick Bergquist, Ryan Williams, Navya Voleti, Adam Sturts, Pratyush Rai, Mouli Ramasamy, Venk Varadan, Omaima A. Ali, Vijay K. Varadan, John P. Boehmer, Alexander Hajduczok
Journal: Journal of the American College of Cardiology (2022)
A Nanocoating Co‐Localizing Nitric Oxide and Growth Factor onto Individual Endothelial Cells Reveals Synergistic Effects on Angiogenesis (Adv. Healthcare Mater. 6/2022)
Authors: Hyejoong Jeong, Daheui Choi, Yoogyeong Oh, Jiwoong Heo, Jinkee Hong
Journal: Advanced Healthcare Materials (2022)

Angiogenesis In article number 2102095 by Jinkee Hong and co-workers, a nanocoating, co-localizing nitric oxide and vascular endothelial growth factor (VEGF), is successfully formed on a surface of endothelial cells, harnessing biocompatible polymers via a layer-by-layer assembly technique. The nanocoating efficiently delivers labile nitric oxide to cells and induces a synergistic effect with VEGF to naturally enhance angiogenesis signals and subsequent vascularization, which can be utilized for stem cell transplantation for vascular regeneration.
Abstract ES8-2: Can radiation replace ALND after positive SLNB?
Authors: R Jagsi
Journal: Cancer Research (2022)

Abstract Growing recognition of the adverse impact of lymphedema on quality of life of survivors of breast cancer has motivated efforts to identify alternatives to axillary lymph node dissection. In some patients who have positive sentinel lymph nodes, radiation therapy may provide a more tolerable alternative to ALND without compromising disease control. This session will focus on the results of the key randomized trials directly evaluating this question: AMAROS and OTOASOR, as well as the implications of other trials that can help to identify patients in whom de-escalation of axillary surgery appears safe. Citation Format: R Jagsi. Can radiation replace ALND after positive SLNB? [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES8-2.
THE INTERSECTION OF CARDIO-OBSTETRICS AND CLINICAL DECISION-MAKING: HYPERTENSIVE EMERGENCY IN PREGNANCY DUE TO CUSHING’S SYNDROME
Authors: Craig C. Morris, Kris Kumar, Ashraf Samhan, Pooja Prasad, Brian Mau, Ibett Colina, Lidija Breznikar McGrath, Abigail M. Khan, Craig S. Broberg
Journal: Journal of the American College of Cardiology (2022)
PERSONALIZING THE OPTIMAL CARDIAC TROPONIN THRESHOLD FOR COVID-19 PROGNOSTICATION BASED ON PRE-EXISTING COMORBIDITIES
Authors: Max Ruge, Jeanne du Fay de Lavallaz, Kelsey T. Danley, Joanne Michelle D. Gomez, Eileen Gajo, Alexandra Sarau, J. Alan Simmons, Anupama Rao, Kim Allan Williams, Annabelle S. Volgman, Karolina Marinescu, Tisha Marie Suboc
Journal: Journal of the American College of Cardiology (2022)
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Christopher J. Sweeney, Ivor J. Percent, Sunil Babu, Jennifer L. Cultrera, Bryan A. Mehlhaff, Oscar B. Goodman, David S. Morris, Ian D. Schnadig, Costantine Albany, Neal D. Shore, Paul R. Sieber, Susan C. Guba, Wei Zhang, Volker Wacheck, Gregory P. Donoho, Anna M. Szpurka, Sophie Callies, Boris Kin Lin, Johanna C. Bendell
Journal: Clinical Cancer Research (2022)

Abstract Purpose: To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) following cancer progression on abiraterone. Patients and Methods: In this double-blind, placebo-controlled phase Ib/II study (NCT02407054), following a lead-in segment for evaluating safety and pharmacokinetics of samotolisib and enzalutamide combination, patients with advanced castration-resistant prostate cancer with progression on prior abiraterone were randomized to receive enzalutamide (160 mg daily)/samotolisib (200 mg twice daily) or placebo. Primary endpoint was progression-free survival (PFS) assessed by Prostate Cancer Clinical Trials Working Group criteria (PCWG2). Secondary and exploratory endpoints included radiographic PFS (rPFS) and biomarkers, respectively. Log-rank tests assessed treatment group differences. Results: Overall, 13 and 129 patients were enrolled in phase Ib and II, respectively. Dose-limiting toxicity was not reported in patients during phase Ib and mean samotolisib exposures remained in the targeted range despite a 35% decrease when administered with enzalutamide. In phase II, median PCWG2-PFS and rPFS was significantly longer in the samotolisib/enzalutamide versus placebo/enzalutamide arm (3.8 vs. 2.8 months; P = 0.003 and 10.2 vs. 5.5 months; P = 0.03), respectively. Patients without androgen receptor splice variant 7 showed a significant and clinically meaningful rPFS benefit in the samotolisib/enzalutamide versus placebo/enzalutamide arm (13.2 months vs. 5.3 months; P = 0.03). Conclusions: Samotolisib/enzalutamide has tolerable side effects and significantly improved PFS in patients with mCRPC with cancer progression on abiraterone, and this may be enriched in patients with PTEN intact and no androgen receptor splice variant 7.
A RARE CASE OF MULTIPLE PULMONARY VEIN STENOSIS ASSOCIATED WITH DERMATOMYOSITIS
Authors: Hardik Fichadiya, Muhammad Atif Masood Noori, Biren D. Patel, Maurvi Bhavsar, Gautam Karteek Visveswaran, Robert J. Sommer, Meherwan Joshi
Journal: Journal of the American College of Cardiology (2022)
A CASE OF MECHANICAL HEMOLYSIS MANAGED BY VALVE-IN-VALVE TRANSCATHETER MITRAL VALVE REPLACEMENT
Authors: Anand Desai, Asim Syed, Hamza Lodhi, Adithya Thomas Mathews, Ramez Morcos, Harris Khan, Enrique Rodriguez-Paz, Tracey Topacio, Kapil Hemant Painter, Houman Khalili, Brijeshwar Singh Maini
Journal: Journal of the American College of Cardiology (2022)
Abstract PD9-11: Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study
Authors: Daniel G. Stover, Adrienne Damicis, Yujing J. Heng, Katharine A. Collier, Elizabeth J. Adams, Kevin H. Kensler, Gabrielle M. Baker, Robert Wesolowski, Sagar Sardesai, Margaret Gatti-Mays, Bhuvaneswari Ramaswamy, A. Heather Eliassen, Susan E. Hankinson, Fred K. Tabung, Rulla M. Tamimi, Sarah Asad
Journal: Cancer Research (2022)

Abstract Purpose: Immune infiltration is associated with better treatment response and outcomes in breast cancer, yet data regarding the role of modifiable patient factors in immune infiltration are limited. Patients and Methods: This population-based, prospective observational study evaluated 882 Nurses’ Health Study (NHS) and NHSII participants diagnosed with invasive breast cancer with detailed exposure and gene expression data. Of these, 262 women (training cohort) had breast tumor immunohistochemistry (IHC) for four canonical immune cell markers: CD8, CD4, CD20, CD163. In this training cohort, 105 published immune cell-specific gene expression signatures were calculated, then lasso regression was used to derive four immune cell-specific scores based on association with IHC. In the remaining 620 patient testing cohort, we evaluated association of each immune-cell specific score as outcomes, with body mass index (BMI) change since age 18, physical activity, and the empirical dietary inflammatory pattern (EDIP) score as predictors, using multivariable-adjusted linear regression. Results: Among women with paired expression/IHC data from breast tumor tissue, we identified robust correlation between novel immune cell-specific expression scores and IHC (Spearman’s rho range 0.42-0.54; all p&amp;lt;0.001). BMI change since age 18 was positively associated with CD4+ (β=0.16; SE=0.06; p=0.009), and CD163+ scores (β=0.14; SE=0.07; p=0.04) in multivariable analyses. Neither physical activity nor EDIP were significantly associated with any immune cell-specific expression score in multivariable analyses. Conclusions: BMI change since age 18 was positively associated with novel CD4+ and CD163+ cell scores in breast cancer, supporting further study of the effect of modifiable factors like weight gain on the immune microenvironment. Citation Format: Daniel G. Stover, Adrienne Damicis, Yujing J. Heng, Katharine A. Collier, Elizabeth J. Adams, Kevin H. Kensler, Gabrielle M. Baker, Robert Wesolowski, Sagar Sardesai, Margaret Gatti-Mays, Bhuvaneswari Ramaswamy, A. Heather Eliassen, Susan E. Hankinson, Fred K. Tabung, Rulla M. Tamimi, Sarah Asad. Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD9-11.